You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
百濟神州(06160.HK)披露治療腫瘤藥物2期臨床試驗結果
阿思達克 12-13 09:49
百濟神州(06160.HK)公布,於美國東部時間12月11日公布一項正在進行的2期試驗的補充的安全性和有效性結果,這是一項評估百悅澤(澤布替尼)在既往經治的、對伊布替尼和或Acalabrutinib不耐受的B細胞惡性腫瘤患者中療效的試驗。有關資料已於第63屆美國血液學會(ASH)年會期間於今日(13日)舉辦的一場小型口頭報告會上披露。 2期臨床試驗的隨訪結果表明,既往接受BTK抑制劑後由於不耐受的不良事件導致治療終止的患者,經百悅澤治療後不太可能復發此類事件。百悅澤治療中,93.8%顯示疾病得到持續控制,同時64.1%顯示疾病緩解情況得到改善。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account